GT
MRTX

Glenmede Trust’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Glenmede Trust’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10
Closed -$1K – 2373
2020
Q3 		$1K Hold
10
– – ﹤0.01% 2419
2020
Q2 		$1K Buy
+10
New +$970 ﹤0.01% 2395
2019
Q4 		– Sell
-75
Closed -$5 – 3154
2019
Q3 		$5 Sell
75
-1,425
-95% -$134K ﹤0.01% 2659
2019
Q2 		$154 Buy
1,500
+660
+79% +$51.4K ﹤0.01% 1256
2019
Q1 		$61 Buy
+840
New +$57.1K ﹤0.01% 1595

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Glenmede Trust's MRTX Position: Q4 2020 in Review

Glenmede Trust sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2020, closing a stake of 10 shares — an estimated $1K sold.

Glenmede Trust first reported a position in MRTX in Q1 2019 and held it in 5 quarters. The position peaked at $1K in Q3 2020. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

  • Glenmede Trust reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 10 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
  • Glenmede Trust's Mirati Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2020.
  • 284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.